Literature DB >> 8585754

Successful treatment of cryptococcal meningitis with amphotericin B colloidal dispersion: report of four cases.

G Valero1, J R Graybill.   

Abstract

Four patients with cryptococcal meningitis were treated with amphotericin B colloidal dispersion because of nephrotoxicity from prior treatment with conventional amphotericin B. The limited experience presented here suggests that amphotericin B colloidal dispersion is efficacious for the treatment of cryptococcal meningitis, despite being undetectable in cerebrospinal fluid, and offers a potential therapeutic alternative for patients who cannot tolerate conventional amphotericin B.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8585754      PMCID： PMC162993          DOI： 10.1128/AAC.39.11.2588

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  4 in total

Review 1.  Amphotericin B: 30 years of clinical experience.

Authors:  H A Gallis; R H Drew; W W Pickard
Journal:  Rev Infect Dis       Date:  1990 Mar-Apr

2.  Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS.

Authors:  R J Coker; M Viviani; B G Gazzard; B Du Pont; H D Pohle; S M Murphy; J Atouguia; J L Champalimaud; J R Harris
Journal:  AIDS       Date:  1993-06       Impact factor: 4.177

3.  Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks.

Authors:  W E Dismukes; G Cloud; H A Gallis; T M Kerkering; G Medoff; P C Craven; L G Kaplowitz; J F Fisher; C R Gregg; C A Bowles; S Shadomy; A M Stamm; R B Diasio; L Kaufman; S Soong; W C Blackwelder
Journal:  N Engl J Med       Date:  1987-08-06       Impact factor: 91.245

4.  Efficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosis.

Authors:  J S Hostetler; K V Clemons; L H Hanson; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191
  4 in total
  4 in total

Review 1.  Carrier effects on biological activity of amphotericin B.

Authors:  J Brajtburg; J Bolard
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

Review 2.  Commonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics.

Authors:  J Singh; B Burr; D Stringham; A Arrieta
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 3.  Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis.

Authors:  R N Brogden; K L Goa; A J Coukell
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

Review 4.  Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome.

Authors:  S Husain; M M Wagener; N Singh
Journal:  Emerg Infect Dis       Date:  2001 May-Jun       Impact factor: 6.883
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.